PACB - パシフィック・バイオサイエンシズ・オブ・カリフォルニア (Pacific Biosciences of California Inc.)

PACBのニュース

   Biotech Sector Lost About $85 Billion in Worst Week in a Year  2021/03/05 18:46:23 Yahoo Finance
(Bloomberg) -- The Nasdaq Biotech Index lost $85 billion this week in its worst drop in a year as funds saw the most money flow out of the sector since last March.The benchmark for biotechnology stocks is on track to close out its third weekly loss in a row.President Joe Biden said this week that the U.S. should have enough Covid-19 vaccines for every adult by May. While investors weigh the need for more medicines and vaccines to address the pandemic, they are using last year’s profits to snap up shares in some of 2020’s more beaten-down industries like banks, travel and leisure. Rising interest rates have also hurt the growth-oriented biotech sector.In the weekly period that ended March 3, $569 million exited the 127 biotech mutual and exchange-traded funds tracked by Piper Sandler’s Christopher Raymond. Still, with fund flows still positive for the year, “it’s too soon to sound the alarm, he said in an interview.“There are moments when there is a very fundamental policy shift, like drug pricing that makes a generalist investor want to shy away from biotech and we haven’t seen any of that yet,” Raymond said.
   Digital Genome Market – Illumina, Inc., PerkinElmer, Inc., Pacific Biosciences of California, Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies Limited  2021/03/02 07:36:49 OpenPR
Digital Genome Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities
   Softbank Reportedly Eyes Billion-Dollar Biotech Bet  2021/02/24 00:05:00 Zero Hedge
Softbank Reportedly Eyes Billion-Dollar Biotech Bet Though SoftBank has denied it, rumors are circulating Tuesday that the Japanese telecom/venture capital giant is planning to invest billions of dollars in the biotech sector. The booming SPAC trend has amplified curiosity about Softbank's next big investment idea, especially amid rumors that the company might pursue a SPAC as the vehicle for its second "Vision Fund", and according to Bloomberg's sources, SB is looking to focus on biotech, a sector that has already been embraced by Wall Street Bets and others betting on microcap biotech stocks. Biotech has been a hot sector for the SPAC trend: this past week alone, Foresite Capital’s second SPAC raised $175 million in its IPO, while two other biotech SPACs, European Biotech Acquisition and Frontier Acquisition, filed to raise a total of $300 million in their Nasdaq debuts. Japan's aging population offers fertile ground for biotech companies looking to solve myriad problems linked to aging.
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts  2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.
   Biotech Sector Lost About $85 Billion in Worst Week in a Year  2021/03/05 18:46:23 Yahoo Finance
(Bloomberg) -- The Nasdaq Biotech Index lost $85 billion this week in its worst drop in a year as funds saw the most money flow out of the sector since last March.The benchmark for biotechnology stocks is on track to close out its third weekly loss in a row.President Joe Biden said this week that the U.S. should have enough Covid-19 vaccines for every adult by May. While investors weigh the need for more medicines and vaccines to address the pandemic, they are using last year’s profits to snap up shares in some of 2020’s more beaten-down industries like banks, travel and leisure. Rising interest rates have also hurt the growth-oriented biotech sector.In the weekly period that ended March 3, $569 million exited the 127 biotech mutual and exchange-traded funds tracked by Piper Sandler’s Christopher Raymond. Still, with fund flows still positive for the year, “it’s too soon to sound the alarm, he said in an interview.“There are moments when there is a very fundamental policy shift, like drug pricing that makes a generalist investor want to shy away from biotech and we haven’t seen any of that yet,” Raymond said.
   Digital Genome Market – Illumina, Inc., PerkinElmer, Inc., Pacific Biosciences of California, Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies Limited  2021/03/02 07:36:49 OpenPR
Digital Genome Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities
   Softbank Reportedly Eyes Billion-Dollar Biotech Bet  2021/02/24 00:05:00 Zero Hedge
Softbank Reportedly Eyes Billion-Dollar Biotech Bet Though SoftBank has denied it, rumors are circulating Tuesday that the Japanese telecom/venture capital giant is planning to invest billions of dollars in the biotech sector. The booming SPAC trend has amplified curiosity about Softbank's next big investment idea, especially amid rumors that the company might pursue a SPAC as the vehicle for its second "Vision Fund", and according to Bloomberg's sources, SB is looking to focus on biotech, a sector that has already been embraced by Wall Street Bets and others betting on microcap biotech stocks. Biotech has been a hot sector for the SPAC trend: this past week alone, Foresite Capital’s second SPAC raised $175 million in its IPO, while two other biotech SPACs, European Biotech Acquisition and Frontier Acquisition, filed to raise a total of $300 million in their Nasdaq debuts. Japan's aging population offers fertile ground for biotech companies looking to solve myriad problems linked to aging.
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts  2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.
   Digital Genome Market Analysis by Potential Revenue | Illumina, PerkinElmer, Pacific Biosciences of California  2020/11/27 14:09:35 OpenPR
Engaged in development of digital genome, owing to greater future prospects of digital genome in the detection of chronic and infectious disease, birth anomalies, drug discovery & development, and diverse clinical applications. Also, market players are adopting inorganic growth strategies
   This Is What Hedge Funds Bought And Sold In Q3: Complete 13F Summary  2020/11/17 03:20:00 Zero Hedge
This Is What Hedge Funds Bought And Sold In Q3: Complete 13F Summary Tyler Durden Mon, 11/16/2020 - 22:20 While we live in a time when the holdings of the top 20 Robinhood "investors" have far more information value for markets and other traders than a glimpse into what hedge funds are doing, not in the least because retail investors are outperforming both the S&P500 and hedge funds 10-to-1… ... unfortunately there is still no regulatory requirement for even superstar retail investors to disclose their holdings, which is why we have to be satisfied with the quarterly 13-F publication spectacle, which just concluded today, and which revealed that even as tech stocks suffered two correction shakeouts since early September, hedge funds mostly stuck with the "safety" of tech stocks during the third quarter heading into the election, even as some hedge funds trimmed Amazon.com as the dominant e-commerce platform thrived amid a pandemic-fueled surge in online shopping, while others sold Netflix Courtesy of Bloomberg, below is a snapshot of what some of the most prominent tech stock additions as disclosed by today's barrage of 13F filings: Coatue Management doubled its holdings of Tesla in the three months ended Sept. 30, making the electric-vehicle maker its second-biggest publicly disclosed holding.
   The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations  2020/11/13 12:40:10 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12) ALX Oncology Holdings Inc (NASDAQ: ALXO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Denali Therapeutics Inc (NASDAQ: DNLI ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (announced preclinical data supporting evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors) Generation Bio Co (NASDAQ: GBIO ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD ) (announced presentation of clinical study data on its investigational therapy KSI-301 in retinal disorders) Kura Oncology Inc (NASDAQ: KURA ) MannKind Corporation (NASDAQ: MNKD ) Myokardia Inc (NASDAQ: MYOK ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Repligen Corporation (NASDAQ: RGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Spero Therapeutics Inc (NASDAQ: SPRO ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) (announced its third-quarter results) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
   Pacific Biosciences of California prices equity offering (NASDAQ:PACB)  2020/11/11 10:44:27 Seeking Alpha
Pacific Biosciences of California (NASDAQ:PACB) has priced underwritten public offering of ~7.4M shares at $14.25/share, for gross proceeds of ~$86.9M. The
   Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 5.2%  2020/10/24 11:50:47 The Olympia Report
Pacific Biosciences of California (NASDAQ:PACB) shares shot up 5.2% during mid-day trading on Thursday . The stock traded as high as $13.86 and last traded at $13.77. 2,846,571 shares were traded during trading, an increase of 11% from the average session volume of 2,570,063 shares. The stock had previously closed at $13.09. Several analysts have […]

calendar